Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC lessened its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 4.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 729,740 shares of the medical research company’s stock after selling 34,478 shares during the period. Exact Sciences makes up approximately 1.2% of Peregrine Capital Management LLC’s portfolio, making the stock its 19th biggest holding. Peregrine Capital Management LLC owned 0.39% of Exact Sciences worth $41,004,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Groupama Asset Managment purchased a new position in shares of Exact Sciences in the third quarter valued at $821,000. ArrowMark Colorado Holdings LLC purchased a new position in Exact Sciences during the 3rd quarter valued at about $28,608,000. Iron Triangle Partners LP acquired a new position in Exact Sciences during the third quarter worth about $27,239,000. Erste Asset Management GmbH purchased a new stake in shares of Exact Sciences in the third quarter valued at about $26,546,000. Finally, Bellevue Group AG grew its position in shares of Exact Sciences by 25.1% in the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock valued at $98,738,000 after purchasing an additional 290,585 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS opened at $49.31 on Tuesday. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The company has a market cap of $9.13 billion, a PE ratio of -42.14 and a beta of 1.24. The stock has a 50 day simple moving average of $55.90 and a 200-day simple moving average of $60.23.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on EXAS shares. Benchmark reaffirmed a “buy” rating and issued a $65.00 target price on shares of Exact Sciences in a research note on Monday, January 13th. Evercore ISI dropped their price target on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Citigroup decreased their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Craig Hallum cut their price objective on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus decreased their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.